Article ISI
ANNALS OF ONCOLOGY  (2023)

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Wainberg, Z. A.; Molena D.; Hyung, W. J.; Omori T.; Cunha Sousa Oliveira, S.; Liberman M.; Castro Oliden V.; Bilici M.; Kurland, J.; Xynos I.; Mann H.